{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:03:44Z","timestamp":1791180224713,"version":"4.1.0"},"reference-count":49,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>The longterm use of tumor necrosis factor (TNF)-\u03b1 blockers is limited by the formation of neutralizing antibodies. To the best of our knowledge, immunogenicity in psoriatic arthritis (PsA) has not been investigated in depth. Our objective was to evaluate the prevalence and significance of TNF-\u03b1 blocker immunogenicity in PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Consecutive patients with PsA treated with either infliximab (IFX), adalimumab (ADA), or etanercept (ETN) &gt; 3 months participated in our cross-sectional study. Their demographic and clinical characteristics, skin and joint disease activity, and records of use of methotrexate (MTX) and other medications were collected. Drug levels (ELISA) and antidrug antibodies (ADAb; Bridging ELISA) were evaluated before the next injection or infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>A total of 93 patients with PsA were recruited (48 receiving ADA, 24 IFX, and 21 ETN), with a mean age of 53 years (range 21\u201383 yrs), composed of 53% women. One-fourth of the patients were concomitantly treated with MTX. Altogether, 77% of the patients demonstrated therapeutic drug levels. High levels of ADAb were found in 29% of patients taking ADA, 21% taking IFX, and 0% taking ETN. ADAb significantly correlated with lower drug levels, higher 28-joint Disease Activity Scores, and higher global assessments. MTX use correlated significantly with a lower prevalence of ADAb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Significant levels of ADAb were present in up to 29% of patients with PsA treated with ADA or IFX. ADAb clearly correlated with low therapeutic drug levels and higher disease activity variables. The use of MTX significantly decreased ADAb prevalence, and its use should be strongly considered in combination with TNF-\u03b1 blocker antibodies in patients with PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.140685","type":"journal-article","created":{"date-parts":[[2014,11,15]],"date-time":"2014-11-15T20:32:02Z","timestamp":1416083522000},"page":"73-78","source":"Crossref","is-referenced-by-count":50,"title":["Prevalence of TNF-\u03b1 Blocker Immunogenicity in Psoriatic Arthritis"],"prefix":"10.3899","volume":"42","author":[{"given":"Michael","family":"Zisapel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Madar-Balakirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Padova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Matz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Maman-Sarvagyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Paran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Litinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Wigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,11,15]]},"reference":[{"key":"2018112909335040000_42.1.73.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2010.01540.x"},{"key":"2018112909335040000_42.1.73.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2536-z"},{"key":"2018112909335040000_42.1.73.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2378-0"},{"key":"2018112909335040000_42.1.73.4","first-page":"163","article-title":"Immunogenicity of infliximab: how to handle the problem?","volume":"70","author":"Baert","year":"2007","journal-title":"Acta Gastroenterol Belg"},{"key":"2018112909335040000_42.1.73.5","first-page":"172","article-title":"Immunogenicity of therapeutic monoclonal antibodies","volume":"5","author":"Pendley","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"2018112909335040000_42.1.73.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0085-0"},{"key":"2018112909335040000_42.1.73.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0189-7"},{"key":"2018112909335040000_42.1.73.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.06.011"},{"key":"2018112909335040000_42.1.73.9","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"2018112909335040000_42.1.73.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"2018112909335040000_42.1.73.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833"},{"key":"2018112909335040000_42.1.73.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"},{"key":"2018112909335040000_42.1.73.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072397"},{"key":"2018112909335040000_42.1.73.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049858"},{"key":"2018112909335040000_42.1.73.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200184"},{"key":"2018112909335040000_42.1.73.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.34680"},{"key":"2018112909335040000_42.1.73.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089979"},{"key":"2018112909335040000_42.1.73.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"2018112909335040000_42.1.73.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8140-3"},{"key":"2018112909335040000_42.1.73.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.021"},{"key":"2018112909335040000_42.1.73.21","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909335040000_42.1.73.22","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"2018112909335040000_42.1.73.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"2018112909335040000_42.1.73.24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.18553\/jmcp.2005.11.5.383","article-title":"Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis","volume":"11","author":"Ollendorf","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"2018112909335040000_42.1.73.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.10302"},{"key":"2018112909335040000_42.1.73.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker124"},{"key":"2018112909335040000_42.1.73.27","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20899"},{"key":"2018112909335040000_42.1.73.28","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50182"},{"key":"2018112909335040000_42.1.73.29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"2018112909335040000_42.1.73.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057745"},{"key":"2018112909335040000_42.1.73.31","doi-asserted-by":"publisher","DOI":"10.1186\/ar3386"},{"key":"2018112909335040000_42.1.73.32","doi-asserted-by":"crossref","unstructured":"Kneepkens EL Wei JC Nurmohamed MT Yeo KJ Chen CY van der Horst-Bruinsma IE Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow up. Ann Rheum Dis 2013 Dec 10 (E-pub ahead of print).","DOI":"10.1136\/annrheumdis-2013-eular.1553"},{"key":"2018112909335040000_42.1.73.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00882.x"},{"key":"2018112909335040000_42.1.73.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.018"},{"key":"2018112909335040000_42.1.73.35","first-page":"171","article-title":"Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study","volume":"148","author":"Cozzani","year":"2013","journal-title":"G Ital Dermatol Venereol"},{"key":"2018112909335040000_42.1.73.36","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.347"},{"key":"2018112909335040000_42.1.73.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108787"},{"key":"2018112909335040000_42.1.73.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2018112909335040000_42.1.73.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2018112909335040000_42.1.73.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201544"},{"key":"2018112909335040000_42.1.73.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2018112909335040000_42.1.73.42","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.7430"},{"key":"2018112909335040000_42.1.73.43","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978"},{"key":"2018112909335040000_42.1.73.44","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2010.536254"},{"key":"2018112909335040000_42.1.73.45","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1515\/cclm-2012-0050","article-title":"Analytical and clinical evaluation of new immunoassay for therapeutic drug monitoring of infliximab and adalimumab","volume":"50","author":"Llinares-Tello","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2018112909335040000_42.1.73.46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem261"},{"key":"2018112909335040000_42.1.73.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.07.019"},{"key":"2018112909335040000_42.1.73.48","first-page":"1","article-title":"Significant associations of antidrug antibody levels with serum drug through and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"0","author":"Chen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2018112909335040000_42.1.73.49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.8347"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:31:59Z","timestamp":1650627119000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,15]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,1]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.3899\/jrheum.140685"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140685","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,15]]}}}